Javier Pinilla-Ibarz, MD, PhD from the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL discusses a new generation PI3K delta inhibitor used in chronic lymphocytic leukemia (CLL) called TGR-1202. Surprisingly TGR-1202 has a significantly better tolerability profile compared to other PI3K delta inhibitors. This interview was recorded at the International Workshop on Chronic lymphocytic Leukemia (iwCLL) 2017 in New York, NY.